Evaluation of the Impact of Elexacaftor/Tezacaftor/Ivacaftor on Aerobic Capacity in Children With Cystic Fibrosis Aged 6–11 Years: Actual Observations and Clinical Perspectives Margarita Pérez-Ruiz, Mats te Bos, Patricia Fernández-García, Cristina de Manuel, Ana Morales-Tirado, Alejandro López-Neyra, Marta Ruiz de Valbuena, Margarita Rubio, Verónica Sanz-Santiago

Elexacaftor/Tezacaftor/Ivacaftor Effectiveness in N1303K Variant in Adult People With Cystic Fibrosis Mariane Gonçalves Martynychen Canan, Caroline Souza Sokoloski, Carolina Rossetti Severo, Samia Zahi Rached, Rodrigo Abensur Athanazio

CC16 Expression Restoration in Sputum of People With Cystic Fibrosis After Initiation of Elexacaftor/Tezacaftor/Ivacaftor Angélique Mottais, Bruno Detry, Ziyu Alessia Qiu, Amandine M. Collin, Marylène Lecocq, Caroline Bouzin, Clara Chamlou, Chloé Bruart, Charlotte de Fays, Bart Vanaudenaerde, Lieven Dupont, Astrid Vermaut, Marianne Schulte, Mieke Boon, Christophe Goubau, Silvia Berardis, Valérie Hox, Antoine Froidure, Charles Pilette, Sophie Gohy